• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌微环境中T细胞的相互作用。

Crosstalk of T cells within the ovarian cancer microenvironment.

作者信息

Chap Bovannak S, Rayroux Nicolas, Grimm Alizée J, Ghisoni Eleonora, Dangaj Laniti Denarda

机构信息

Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland.

Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland.

出版信息

Trends Cancer. 2024 Dec;10(12):1116-1130. doi: 10.1016/j.trecan.2024.09.001. Epub 2024 Sep 27.

DOI:10.1016/j.trecan.2024.09.001
PMID:39341696
Abstract

Ovarian cancer (OC) represents ecosystems of highly diverse tumor microenvironments (TMEs). The presence of tumor-infiltrating lymphocytes (TILs) is linked to enhanced immune responses and long-term survival. In this review we present emerging evidence suggesting that cellular crosstalk tightly regulates the distribution of TILs within the TME, underscoring the need to better understand key cellular networks that promote or impede T cell infiltration in OC. We also capture the emergent methodologies and computational techniques that enable the dissection of cell-cell crosstalk. Finally, we present innovative ex vivo TME models that can be leveraged to map and perturb cellular communications to enhance T cell infiltration and immune reactivity.

摘要

卵巢癌(OC)代表了高度多样化的肿瘤微环境(TME)生态系统。肿瘤浸润淋巴细胞(TILs)的存在与增强的免疫反应和长期生存相关。在本综述中,我们展示了新出现的证据,表明细胞间相互作用严格调节TILs在TME中的分布,这突出了更好地理解促进或阻碍OC中T细胞浸润的关键细胞网络的必要性。我们还介绍了能够剖析细胞间相互作用的新兴方法和计算技术。最后,我们展示了创新的离体TME模型,可用于绘制和干扰细胞通讯,以增强T细胞浸润和免疫反应性。

相似文献

1
Crosstalk of T cells within the ovarian cancer microenvironment.卵巢癌微环境中T细胞的相互作用。
Trends Cancer. 2024 Dec;10(12):1116-1130. doi: 10.1016/j.trecan.2024.09.001. Epub 2024 Sep 27.
2
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy.关键免疫T细胞群体在不同免疫原性潜能和免疫治疗反应可能性的恶性肿瘤中的差异浸润。
Cells. 2024 Dec 3;13(23):1993. doi: 10.3390/cells13231993.
3
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8 TILs based on mutation status in epithelial ovarian cancers.基于上皮性卵巢癌突变状态的 CD8 TIL 独特免疫特征和差异化抗 PD-1 介导再激活潜能。
J Immunother Cancer. 2024 Jul 4;12(7):e009058. doi: 10.1136/jitc-2024-009058.
4
Precision-cut tumor tissue slices, a novel tool to study the tumor microenvironment interactions with chimeric antigen receptor (CAR) T cells.精密切割肿瘤组织切片,一种研究肿瘤微环境与嵌合抗原受体(CAR)T细胞相互作用的新工具。
PLoS One. 2025 Aug 8;20(8):e0327322. doi: 10.1371/journal.pone.0327322. eCollection 2025.
5
Adoptive T cell therapy for ovarian cancer.卵巢癌的过继性 T 细胞疗法。
Gynecol Oncol. 2024 Jul;186:77-84. doi: 10.1016/j.ygyno.2024.04.001. Epub 2024 Apr 10.
6
Engineered 3D ex vivo models to recapitulate the complex stromal and immune interactions within the tumor microenvironment.用于概括肿瘤微环境内复杂基质和免疫相互作用的工程化三维体外模型。
Biomaterials. 2024 Mar;305:122428. doi: 10.1016/j.biomaterials.2023.122428. Epub 2023 Dec 19.
7
Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.HPV 抗原表达的鳞状细胞癌(SCC)模型中,肿瘤免疫微环境的差异与肿瘤进展或肿瘤消除相关。
Front Immunol. 2024 Jul 11;15:1405318. doi: 10.3389/fimmu.2024.1405318. eCollection 2024.
8
Transglutaminase 2 regulates ovarian cancer metastasis by modulating the immune microenvironment.转谷氨酰胺酶2通过调节免疫微环境来调控卵巢癌转移。
Front Immunol. 2025 Jul 24;16:1639853. doi: 10.3389/fimmu.2025.1639853. eCollection 2025.
9
Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer.绘制卵巢癌中空间组织和遗传细胞状态调控因子图谱以靶向免疫逃逸。
Nat Immunol. 2024 Oct;25(10):1943-1958. doi: 10.1038/s41590-024-01943-5. Epub 2024 Aug 23.
10
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.早期三阴性乳腺癌中肿瘤糖皮质激素受体的高表达与调节性T细胞浸润增加有关。
Breast Cancer Res Treat. 2025 Feb;209(3):563-572. doi: 10.1007/s10549-024-07515-3. Epub 2024 Nov 23.

引用本文的文献

1
Therapeutic landscape of ovarian cancer: recent advances and emerging therapies.卵巢癌的治疗格局:最新进展与新兴疗法
Biomark Res. 2025 Aug 12;13(1):103. doi: 10.1186/s40364-025-00818-7.
2
Worldwide Research Trends on the Immunotherapy-Based Treatment of Ovarian Cancers: A Bibliometric and Visual Analysis.基于免疫疗法的卵巢癌治疗的全球研究趋势:文献计量与可视化分析
J Multidiscip Healthc. 2025 Jul 25;18:4197-4217. doi: 10.2147/JMDH.S526280. eCollection 2025.
3
Role of cellular prion protein in mouse granulosa cells and its effects on ovarian function in knockout mice.
细胞朊蛋白在小鼠颗粒细胞中的作用及其对基因敲除小鼠卵巢功能的影响。
Mol Med Rep. 2025 Oct;32(4). doi: 10.3892/mmr.2025.13630. Epub 2025 Jul 25.
4
Identification of parthanatos-related molecular subtypes and development of prognostic risk models in ovarian cancer based on multi-omics analysis.基于多组学分析的卵巢癌中PARP-1依赖性坏死相关分子亚型的鉴定及预后风险模型的建立
J Ovarian Res. 2025 Jul 2;18(1):137. doi: 10.1186/s13048-025-01726-y.
5
Editorial: Vital role of innate immunity in cancer immunotherapy.社论:天然免疫在癌症免疫治疗中的重要作用。
Front Immunol. 2025 May 21;16:1594009. doi: 10.3389/fimmu.2025.1594009. eCollection 2025.
6
A noncanonical role of SAT1 enables anchorage independence and peritoneal metastasis in ovarian cancer.SAT1的一种非经典作用促使卵巢癌发生锚定非依赖性和腹膜转移。
Nat Commun. 2025 Apr 3;16(1):3174. doi: 10.1038/s41467-025-58525-8.
7
Immunotherapy in Recurrent Ovarian Cancer.复发性卵巢癌的免疫治疗
Biomedicines. 2025 Jan 12;13(1):168. doi: 10.3390/biomedicines13010168.